NuVasive, Inc. (NUVA) Stock Rating Lowered by TheStreet

NuVasive, Inc. (NASDAQ:NUVA) was downgraded by TheStreet from a “b-” rating to a “c+” rating in a research report issued on Friday.

NUVA has been the topic of a number of other research reports. Royal Bank Of Canada restated a “buy” rating and issued a $75.00 price target on shares of NuVasive in a research note on Tuesday, October 10th. Morgan Stanley reiterated an “equal weight” rating and set a $88.00 price objective (up previously from $84.00) on shares of NuVasive in a research report on Tuesday, July 25th. Needham & Company LLC cut NuVasive from a “hold” rating to an “underperform” rating in a research report on Monday, August 28th. BTIG Research reiterated a “buy” rating and set a $74.00 price objective (down previously from $82.00) on shares of NuVasive in a research report on Wednesday, October 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $90.00 price objective on shares of NuVasive in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $75.77.

Shares of NuVasive (NASDAQ:NUVA) traded up 2.74% during trading on Friday, reaching $53.61. 194,088 shares of the company were exchanged. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 84.43 and a beta of 1.04. NuVasive has a one year low of $49.25 and a one year high of $81.68. The company has a 50 day moving average price of $57.00 and a 200-day moving average price of $69.32.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. NuVasive had a return on equity of 7.19% and a net margin of 4.69%. The business had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter in the prior year, the business earned $0.40 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts predict that NuVasive will post $1.99 EPS for the current year.

WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/17/nuvasive-inc-nuva-stock-rating-lowered-by-thestreet.html.

In related news, EVP Peter Michael Leddy acquired 7,850 shares of the stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $63.88 per share, for a total transaction of $501,458.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gregory T. Lucier acquired 5,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $66.22 per share, with a total value of $331,100.00. The disclosure for this purchase can be found here. Insiders have bought 14,850 shares of company stock valued at $955,598 over the last 90 days. 1.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. FNY Partners Fund LP bought a new position in shares of NuVasive during the first quarter worth about $112,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock worth $146,000 after purchasing an additional 158 shares in the last quarter. Howard Hughes Medical Institute increased its holdings in NuVasive by 82.8% in the second quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock worth $159,000 after purchasing an additional 936 shares in the last quarter. US Bancorp DE

NUVA has been the topic of a number of other research reports. Royal Bank Of Canada restated a “buy” rating and issued a $75.00 price target on shares of NuVasive in a research note on Tuesday, October 10th. Morgan Stanley reiterated an “equal weight” rating and set a $88.00 price objective (up previously from $84.00) on shares of NuVasive in a research report on Tuesday, July 25th. Needham & Company LLC cut NuVasive from a “hold” rating to an “underperform” rating in a research report on Monday, August 28th. BTIG Research reiterated a “buy” rating and set a $74.00 price objective (down previously from $82.00) on shares of NuVasive in a research report on Wednesday, October 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $90.00 price objective on shares of NuVasive in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $75.77.

Shares of NuVasive (NASDAQ:NUVA) traded up 2.74% during trading on Friday, reaching $53.61. 194,088 shares of the company were exchanged. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 84.43 and a beta of 1.04. NuVasive has a one year low of $49.25 and a one year high of $81.68. The company has a 50 day moving average price of $57.00 and a 200-day moving average price of $69.32.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. NuVasive had a return on equity of 7.19% and a net margin of 4.69%. The business had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter in the prior year, the business earned $0.40 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts predict that NuVasive will post $1.99 EPS for the current year.

WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/17/nuvasive-inc-nuva-stock-rating-lowered-by-thestreet.html.

In related news, EVP Peter Michael Leddy acquired 7,850 shares of the stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $63.88 per share, for a total transaction of $501,458.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gregory T. Lucier acquired 5,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were bought at an average price of $66.22 per share, with a total value of $331,100.00. The disclosure for this purchase can be found here. Insiders have bought 14,850 shares of company stock valued at $955,598 over the last 90 days. 1.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. FNY Partners Fund LP bought a new position in shares of NuVasive during the first quarter worth about $112,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock worth $146,000 after purchasing an additional 158 shares in the last quarter. Howard Hughes Medical Institute increased its holdings in NuVasive by 82.8% in the second quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock worth $159,000 after purchasing an additional 936 shares in the last quarter. US Bancorp DE increased its holdings in NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock worth $180,000 after purchasing an additional 41 shares in the last quarter. Finally, Honkamp Krueger Financial Services Inc. bought a new stake in NuVasive in the second quarter worth approximately $201,000.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply